1461 citations
,
March 2004 in “Annals of oncology” This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” This study observed early cardiac effects in young minipigs following high-dose doxorubicin chemotherapy, with a decrease in heart function and changes in cardiac MRI measurements compared to controls.
27 citations
,
August 1984 in “Experimental and Molecular Pathology” 
13 citations
,
July 2024 in “Heart Failure Reviews” This review compiles data on how the apelinergic system may protect against heart damage caused by doxorubicin cancer treatment, suggesting its potential to mitigate cardiotoxicity, though further research in chronic models is needed to confirm these effects and mechanisms.
45 citations
,
November 1979 in “British Journal of Dermatology” This report describes a case of hypertrichosis associated with minoxidil use and suggests that nearly all patients on this drug may experience this side effect.
24 citations
,
February 2016 in “PubMed” This study found that royal jelly may have a cardioprotective effect against paclitaxel-induced damage in rats by reducing oxidative and nitrosative stress, lowering cardiac biomarker levels, and mitigating heart tissue injuries.
19 citations
,
October 2009 in “Bioorganic & Medicinal Chemistry Letters” This study found that a thyroid hormone receptor ẞ subtype-selective thyromimetic was effective in promoting hair growth in mouse and monkey models when applied topically.
15 citations
,
August 2008 in “Toxicology Letters” This study found that minoxidil induced cardiovascular toxicity in marmosets at higher doses than those affecting dogs, potentially due to the drug's exaggerated pharmacological effects.
4 citations
,
August 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil does not cause tachycardia in hair loss patients.
2 citations
,
January 2012 This study suggests that chitosan-enhanced human serum albumin nanoparticles could serve as a safe and effective carrier for delivering anticancer drugs like tamoxifen.
January 2023 in “Discovery medicine” This study found that Cepharanthine may mitigate doxorubicin-induced senescence by reducing SA-β-Gal activity and restoring autophagy in cell models, offering insights for antiaging drug development.
This chapter reviews the structure, pharmacokinetics, and clinical applications of PEGylated liposomes and reports no new research findings.
October 2023 in “Biomedical science and engineering” Innovative methods are reducing animal testing and improving biomedical research.
January 2025 in “Nanoscale” This study reports that a new boron/nitrogen-doped carbon nano-onion-based delivery system for doxorubicin enhanced its uptake and anticancer effects in specific cancer cell types, while reducing cardiotoxicity in human heart cells.
February 2023 in “Journal of Korean Medical Association” This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.
63 citations
,
February 2013 in “Human cell” In this study using an animal model, researchers found that PEGL-DOX, unlike DOX, causes Hand-Foot Syndrome due to reactive oxygen species interacting with skin tissue, leading to skin-specific inflammatory responses.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
21 citations
,
May 1989 in “Advanced Drug Delivery Reviews” This review discusses the enhanced permeability and retention (EPR) effect as a mechanism for targeted drug delivery in cancer therapy and reports no new clinical results.
June 2026 in “Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)” This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.
January 2024 in “Scripta Medica” This review highlights the potential of nanoparticle delivery systems to mitigate doxorubicin's adverse effects and enhance its effectiveness, while discussing the integration of nanotechnology with Streptomyces-derived compounds to potentially advance future cancer therapies.
1108 citations
,
January 2018 in “Dalton transactions” This review discusses the multiple severe side effects of cisplatin, carboplatin, and oxaliplatin in cancer treatment and reports no new clinical results; the authors emphasize the need for careful monitoring and supportive care to manage these effects.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.
12 citations
,
September 2015 in “Drug Design Development and Therapy” This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.
11 citations
,
June 2025 in “Polymers” This review reports on recent surfactant-based niosome formulations, including those with polysaccharides, for versatile drug delivery applications such as ocular, oral, and transdermal settings, while discussing their limitations and potential prospects.
1 citations
,
January 2021 in “Elsevier eBooks” This study found that olive and olive oil may significantly reduce cardiovascular disease risk, cholesterol, and blood pressure, while offering antioxidant protection through bioactive metabolites like oleuropein.
This scoping review identifies various pharmacological agents and five key mechanistic strategies being studied in vivo to mitigate multi-organ toxicity caused by cytarabine, with apraglutide and N-acetylcysteine highlighted as promising candidates for clinical application.
January 1989 in “Side effects of drugs annual” This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.
January 1982 in “Clin-Alert” Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.